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iomarkers in Stroke
hen Will They Impact Care?*
hristopher B. Granger, MD,
aniel T. Laskowitz, MD, MHS
urham, North Carolina
arge, well-defined patient datasets, improved statistical
echniques, and interest by the clinical and research com-
unities have enabled the development of models to predict
utcome in patients with cardiovascular disease. A number
f biomarkers, including troponin and B-type natriuretic
eptide (BNP), provide important independent prognostic
nd diagnostic information and are important variables in
isk models. Both the American (1) and European
2) guidelines for management of non–ST-segment eleva-
ion acute coronary syndromes have made quantitative risk
tratification a Class I recommendation. This recommen-
ation is based on studies showing that risk stratification
an identify which patients derive optimal benefit from
arious treatments, such as an early invasive strategy (3), or
se of more potent antithrombotic therapy (4). In contrast
o cardiac disease, there is a paucity of validated markers in
schemic stroke, and the American Heart Association makes
o recommendations regarding their use in risk stratifica-
ion (5). Nevertheless, risk models that enable clinicians to
etermine prognosis of stroke patients could be useful for
ecisions about intensity of monitoring and treatment, as
ell as for risk adjustment for observational research or
uality improvement studies.
See page 1045
Evaluation of biomarkers for the prediction, diagnosis,
lassification, and prognosis of stroke has been a fertile
round for investigation (6,7). Because diagnostic uncer-
ainty may contribute to the underuse of fibrinolytic therapy
nd other targeted therapies, a biomarker-based test that
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ant for Astute Medical, Inc.ould aid in establishing the diagnosis and etiology of stroke
ould have potential for significant clinical impact. The
dentification of biochemical markers of cerebral ischemia
as proven challenging for a variety of reasons, including the
omplexity of the ischemic cascade and presence of the
lood-brain barrier. Thus, although statistical associations
ith stroke have been demonstrated with individual markers
f inflammation, glial activation, and neuronal injury (7), no
ingle biomarker has ever been demonstrated to be clinically
seful as a standalone diagnostic test. One way to address
his difficulty is by simultaneously evaluating multiple
iomarkers that contribute complementary information.
reliminary studies suggest that such a biomarker panel
ay add time-sensitive diagnostic information in the
arly evaluation of stroke (6).
A biomarker that predicts functional outcome after stroke
ould also play an important role in clinical decision
aking. Prognosis in stroke has been shown to be related to
atient factors such as age and initial neurological deficit as
ssessed by the National Institutes of Health Stroke Scale
NIHSS) (8,9). Although several studies have demonstrated
ssociations between biomarkers of inflammation and out-
ome, none of these studies has demonstrated significant
ncremental predictive capacity over traditional historical
nd clinical factors, thus limiting their clinical significance.
In this issue of the Journal, Katan et al. (10) demonstrate
hat a novel biomarker, midregional pro-atrial natriuretic
eptide (MR-proANP), is a powerful and independent
arker of outcome following ischemic stroke. Using a
ingle-center cohort of 362 patients with ischemic stroke,
hey found that MR-proANP levels were associated with
everity of stroke, history of heart failure, and atrial fibril-
ation. Elevation of MR-proANP was strongly associated
ith mortality and functional outcome at 90 days. The
uthors observed a 4-fold increased risk of poor outcome
ssociated with increasing quartiles of midregional pro-
NP levels. A model incorporating pro-ANP and the NIH
troke scale provided excellent discrimination of risk, with a
-index of 0.92. Moreover, MR-proANP elevation was
elated to etiology of stroke, as higher levels were found in
atients with cardioembolic stroke, even after adjusting for
eart failure and atrial fibrillation. The same investigators,
sing the same dataset and methodology, have previously
emonstrated that another biomarker, copeptin, a fragment
f pro-vasopression, was also independently related to death
nd especially to functional recovery (11). MR-proANP
rovided prognostic information that was independent from
opeptin and appeared to be more strongly predictive of
eath.
Brain natriuretic peptide (BNP) has been shown to be a
owerful prognostic biomarker in patients with heart failure
12) and even in a general population (13). Studies have also
emonstrated elevations of BNP in the setting of acute
troke (6) and prognostic importance of BNP in patients
uffering ischemic stroke (7). It remains unclear whether the
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September 21, 2010:1054–5 Biomarkers in Strokeidely available BNP assays would have performed as well
s MR-proANP in this dataset.
This study addresses the early phases of evaluation (14) of
R-pro-ANP as a potential risk marker following stroke:
roof of concept that the marker is higher in patients with
he event, prospective validation that the marker is predic-
ive in a prospective cohort, and incremental value over
linical variables (Table 1). Although an important advance,
he current study was performed at a single center with only
4 deaths, and the results need to be validated in an
ndependent study. A number of important questions re-
ain. Does this biomarker change predicted risk enough to
lter recommended therapy? Does use of the biomarker
esult in improved care and clinical outcomes? And is it cost
ffective? Although challenging, these questions must be
nswered before biomarkers will inform and improve stroke
are.
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